Best for Sleep
This page summarizes what public source records show about peptides most frequently discussed in connection with sleep. Each entry is reviewed by the depth of clinical evidence and current regulatory status — not by popularity or social media attention. The compounds listed here are investigational research peptides with limited or dated human sleep data and no FDA approval for any sleep indication. This is an evidence curation, not a recommendation to take any compound. No dosing, purchasing, or treatment guidance is provided.
DSIP
The most directly sleep-associated peptide in the research record, with dated human clinical studies reporting mixed effects on sleep architecture.
Evidence level: Peer reviewed (dated human studies, no modern RCTs)
Regulatory status: Not FDA-approved — investigational, listed for FDA advisory committee discussion
DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide originally isolated from rabbit brain extract in the 1970s and reported to modulate sleep patterns. Early clinical studies from the 1970s–1980s investigated DSIP for sleep induction in humans, but results were mixed and inconclusive — some trials reported modest effects on sleep architecture, others found no significant benefit. The clinical literature is dated and has not been advanced with modern randomized controlled trials. Pharmacology reviews describe DSIP as having reported sleep-modulating activity, but its clinical significance remains unestablished. DSIP is not FDA-approved for any indication. It is listed for discussion at the July 2026 FDA Pharmacy Compounding Advisory Committee meeting and appears on the FDA bulk drug substances risk list for compounded products. Online wellness communities discuss DSIP as a sleep aid despite the lack of modern clinical evidence supporting its use.
Epitalon
Researched for pineal gland and telomere biology with indirect theoretical links to circadian regulation, but no direct human sleep trials.
Evidence level: Peer reviewed (preclinical and single-group studies, no human sleep trials)
Regulatory status: Not FDA-approved — investigational, listed for FDA advisory committee discussion
Epitalon (Ala-Glu-Asp-Gly) is a tetrapeptide studied primarily in the context of pineal gland function and telomere biology. Research from the Khavinson group reports that Epitalon increases telomerase activity in human somatic cells, and reviews discuss its potential geroprotective effects. The pineal gland regulates melatonin secretion and circadian rhythms, providing a theoretical biological link to sleep regulation, but no direct clinical trials of Epitalon for sleep outcomes have been published. The evidence base rests primarily on preclinical data and studies from a single Russian research group, lacking independent Western replication. Epitalon is not FDA-approved for any indication. It is listed for discussion at the July 2026 FDA Pharmacy Compounding Advisory Committee meeting and appears on the FDA bulk drug substances risk list. Online longevity content promotes Epitalon as an anti-aging peptide, and some discussions extend to sleep and recovery claims, despite the absence of large-scale human clinical trials for any indication.
Both peptides on this page are investigational research peptides with no FDA approval for sleep. DSIP has only dated clinical literature from the 1970s–1980s with mixed and inconclusive results and no modern randomized controlled trials. Epitalon is researched for pineal gland and telomere biology, not directly for sleep induction, and its evidence base comes primarily from a single Russian research group without independent Western replication. Sleep-promotion claims found in online wellness communities should not be conflated with established clinical evidence. Update this page if modern human trials are published or if regulatory status changes.
Source records are stored in the repo and linked from this page.
Clinical studies of delta sleep-inducing peptide (DSIP) in human sleep, dating to the 1970s-1980s, with mixed and inconclusive results. The DSIP clinical literature is old and has not been advanced with modern trials.
Reviews of DSIP pharmacology describe it as a nonapeptide isolated from rabbit brain extract with reported sleep-modulating activity, though clinical significance remains unestablished.
Studies by Khavinson and colleagues reporting that Epitalon (Ala-Glu-Asp-Gly) increases telomerase activity in human somatic cells. Research is primarily from a single Russian research group and lacks independent Western replication.
Reviews of Epitalon and related peptides in the context of aging biology, noting that telomerase and longevity claims rest on preclinical data from limited research groups without large-scale human clinical trials.
FDA advisory committee meeting notice listing multiple peptide bulk substances scheduled for discussion.
FDA page summarizing bulk drug substances that may present significant safety risks in compounding contexts.